Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Study to trace palliative treatment options for Metastatic triple negative breast cancer MTNBC patients who progress beyond second line chemotherapy through open discussions
*Corresponding Author:
Copyright: © 2020 . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
A case presentation, of 42 year old premenopausal woman consulted at my clinic since since 2018 until present. She has family history of breast cancer in the family, her first line eldest maternal aunt died of breast cancer in 1998. She is HIV negative.She was diagnosed with a triple negative breast cancer. Ki 67 is 30%. Invasive ductal carcinoma type. T4B N3.The tumor/mass was too big to be resected with no presenting cormobities. Stage 3 C. Method. Prospective treatment with 1st line and 2nd line chemoregimens, follow-up and patient disease progressed to metastasis or stage 4 disease. Results. In June 2020,Patient in stable condition and no disease progression. The biggest point of discussion today is whether to combine a targeted therapy to nab paclitaxel or not to achieve better progression control results.
